The impact of PD-L1 polymorphisms on the efficacy of immune checkpoint inhibitors depends on the tumor proportion score: a retrospective study
The rs2282055 genotype may help in selecting cases from the TPS-negative patient population that may benefit from ICI therapy.
Authors
- Hironori Yoshida (ORCID: https://orcid.org/0000-0002-1676-0173)
- Takashi Nomizo (ORCID: https://orcid.org/0000-0002-4328-3042)
- Keiichiro Suminaga
- H Ozasa
Institutions
- Kyoto University (JP)
- Kyoto University Hospital (JP)
Publication Details
- Journal
- Journal of Cancer Research and Clinical Oncology
- Published
- 2025-02-04
- DOI
- https://doi.org/10.1007/s00432-024-06081-x
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 3.14